Company Profile: Volcano makes intravascular-ultrasound products.Closing Price: $24.28 (Sept. 17) One-Year Stock Performance: 48% Wassung's Take: "Volcano is a play on what I'd call better technology in analyzing cardiac events. Their core technology is intravenous ultrasound and functional measurement. Effectively, when someone has a cardiac event, this company provides an ultrasound in arteries, giving doctors better data to show where the challenges are. The data has proved that you get better outcomes of placing the stent in the right place. Unfortunately, it's a big issue for Americans and for global patients, but this provides better technology than the old standard. This will look expensive on a P/E basis, as it just crossed the profitability mark over the last year. On a sales basis, though, you're looking at a stock at 3.5 times revenue, which is how investors should look at health-care companies in this stage of their life cycle." Analyst Consensus: Ten research firms follow Volcano, and nearly all of them say investors should buy the stock. One has a "hold" rating.